Teens Left Behind? New Data on GLP-1 Prescribing Disparities in Youth Obesity
A 2026 JAMA Pediatrics analysis shows teens of color and low-income backgrounds receive GLP-1 prescriptions far less often than peers despite similar obesity rates.
Teens Left Behind? New Data on GLP-1 Prescribing Disparities in Youth Obesity
Featured answer (40–60 words): A March 2026 JAMA Pediatrics analysis of 1.2 million electronic health records found that U.S. adolescents from Black, Hispanic, and Medicaid-insured households were 62–72 percent less likely to receive semaglutide or tirzepatide prescriptions than White or privately insured peers, even after adjusting for body-mass index and comorbidities.[1]
Last updated August 2026
- GLP-1 prescriptions for teens surged 10-fold from 2022–2025 but remain <2% of all eligible youth with obesity.[1]
- Black adolescents had a 0.8% prescription rate versus 2.9% for White adolescents.[1]
- Wegovy (semaglutide) is FDA-approved for obesity in ages 12+; tirzepatide use in teens is off-label.[2],[3]
- Average monthly out-of-pocket cost exceeds $1,350 without insurance coverage.[4]
- Untreated adolescent obesity often tracks into adulthood, doubling cardiovascular risk.[5]
- New national data confirm stark inequities in GLP-1 access among U.S. teens.
- Insurance hurdles, high out-of-pocket costs, and implicit bias all contribute.
- Early intervention matters: adolescent obesity often persists into adulthood.
- Multifaceted policy, payer, and clinical solutions are needed to close the gap.
What Did the March 2026 Study Reveal?
The March 2026 JAMA Pediatrics analysis mined de-identified records from 78 health systems between January 2022 and December 2025.[1] Researchers identified 123,497 patients aged 12–17 with body-mass index (BMI) ≥ 95th percentile. Only 2,811 (2.3%) received any GLP-1 receptor agonist (GLP-1 RA) prescription. Black, Hispanic, and publicly insured adolescents were significantly under-represented even after controlling for age, sex, BMI z-score, type 2 diabetes status, and geographic region.
| Group | Eligible Teens (n) | Prescriptions (n) | Rate % |
|---|---|---|---|
| White, privately insured | 42,018 | 1,231 | 2.9 |
| Black, privately insured | 18,760 | 151 | 0.8 |
| Hispanic, privately insured | 21,606 | 306 | 1.4 |
| All races, Medicaid | 29,744 | 133 | 0.4 |
Notably, tirzepatide represented 18% of all GLP-1 prescriptions despite its adult-only obesity indication, hinting at growing off-label use.
Why Do Racial and Socio-Economic Gaps Exist?
Multiple, overlapping barriers explain the disparity:
- Insurance coverage. Medicaid formularies in 39 states exclude Wegovy for adolescents, requiring lengthy prior authorization.[4]
- High cost. The wholesale acquisition cost (WAC) for Wegovy 2.4 mg pens is about $1,349 per month; tirzepatide (Zepbound) is similar.[4]
- Specialist access. Pediatric endocrinologist shortages disproportionately affect rural and low-income urban areas.
- Implicit bias. Studies show clinicians underestimate treatment adherence among minority youth, leading to fewer prescriptions.[6]
- Parental trust and awareness. Survey data indicate lower familiarity with GLP-1 safety among families of color.
How Might Limited Access Affect Long-Term Health?
Youth obesity often tracks into adulthood; 80% of teens with obesity become adults with obesity.[5] Early pharmacologic intervention with GLP-1 RAs can cut BMI by 15–18 percent and improve blood-pressure and lipid profiles within 68 weeks.[2] Without equitable access, disparities in type 2 diabetes, hypertension, and cardiovascular disease will likely widen.
Which Policy Changes Could Improve Equity?
Experts suggest a layered approach:
- Medicaid parity laws. Mandating coverage for all FDA-approved anti-obesity medications in children aged 12+ could eliminate a key financial barrier.
- Outcome-based contracts. Manufacturers and payers can tie payment to documented BMI reduction, de-risking coverage.
- School-based screening and referral. Embedding BMI and cardiometabolic risk screening in school health programs can identify candidates earlier.
- Telehealth expansion. Virtual visits lower travel burdens and can connect teens to pediatric obesity specialists. See our telehealth guide for what to expect.
Not sure if a GLP-1 is right for your teen? Compare the factors below, then discuss with a qualified pediatric provider.
| Consideration | GLP-1 Therapy | Intensive Lifestyle Program | Bariatric Surgery |
|---|---|---|---|
| Typical BMI reduction (12-18 mo) | -15–20 % | -3–5 % | -25–30 % |
| FDA age eligibility | Semaglutide 12+ yr | All ages | Usually 14+ yr |
| Insurance coverage | Variable, often limited | Widely covered | More consistent |
| Invasiveness | Weekly injection | None | Surgical |
| Long-term data | Up to 2 yr | Decades | Decades |
How Can Clinicians Reduce Prescribing Bias?
Clinicians can adopt standardized protocols to ensure that every teen meeting FDA criteria is offered evidence-based options. Steps include using BMI z-score triggers in electronic health records, employing shared decision-making tools, and completing implicit-bias training modules endorsed by the American Academy of Pediatrics.
Are Lifestyle and Surgical Options Equally Accessible?
Even non-pharmacologic interventions exhibit access gaps. Community-based lifestyle programs are scarcer in majority-Black neighborhoods, and only 5% of teens undergoing metabolic and bariatric surgery (MBS) are Black, despite equal eligibility.[7] Closing GLP-1 gaps should happen alongside broader obesity-care reforms.
When to Contact Your Healthcare Provider
- Severe or persistent abdominal pain
- Repeated vomiting or signs of dehydration
- New mood changes or suicidal thoughts
- Dysphagia (difficulty swallowing) or persistent heartburn
- Signs of allergic reaction: rash, swelling of face or throat, trouble breathing
Scientific References
- GLP-1 Receptor Agonist Prescriptions for Adolescents With Obesity and Associated Disparities. JAMA Pediatrics. 2026;180(3):334-336.
- Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. NEJM. 2022;387:2245-57.
- Wegovy (semaglutide) Prescribing Information. DailyMed. Accessed July 2026.
- Childhood Obesity Facts. CDC. Updated May 2026.
- Zhang Y et al. GLP-1RA Therapy in Children and Adolescents with Obesity: Network Meta-analysis. Diabetes Care. 2026;49(7):e123-e133.
- Disparities in Adolescent and Young Adult Obesity Medication Dispensing: 2020-2025. Obesity. 2026;34(4):611-620.
- GLP-1 RA and Bariatric Surgery Utilization Among Adolescents and Young Adults. JAMA Pediatrics. 2026;180(7):785-787.
Frequently Asked Questions
Is semaglutide actually approved for teens?
Yes. The FDA approved Wegovy (semaglutide 2.4 mg weekly) in December 2022 for adolescents aged 12 years and older with obesity. [3]
Why is tirzepatide prescribed off-label in teens?
Tirzepatide is currently FDA-approved for adults only, but some pediatric endocrinologists prescribe it when lifestyle therapy and semaglutide are ineffective. Off-label use relies on clinician judgment and informed consent.
Can my child get GLP-1 therapy through telehealth?
In most states, yes. Virtual pediatric obesity clinics can evaluate, prescribe, and ship medication after required labs. Learn the process in our guide on online prescriptions .
How long does treatment last?
Clinical trials followed adolescents for up to 104 weeks. Most experts recommend continuing therapy as long as benefits outweigh risks, similar to chronic asthma or diabetes medications. [2]
Will insurance cover Wegovy for my teen?
Coverage varies. About 70% of commercial plans now cover pediatric Wegovy with prior authorization, while most state Medicaid programs do not. Check your plan’s formulary and appeal if denied.
What are common side effects?
Nausea, vomiting, and diarrhea are most common and usually improve over time. Rare but serious risks include pancreatitis and gallbladder disease. [3]
Does weight regain occur after stopping?
Yes. Studies in adults and teens show partial weight regain within 6–12 months of discontinuation, underlining the importance of ongoing lifestyle support.
Medications discussed in this guide
Educational overviews — dosing, side effects, cost and how to talk to a provider.
